 Manojkumar Bupathi
Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Camptothecin | 7 | 2024 | 123 | 1.630 |
Why?
| | Carcinoma, Transitional Cell | 7 | 2025 | 70 | 1.120 |
Why?
| | Antibodies, Monoclonal, Humanized | 8 | 2025 | 908 | 1.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2024 | 1791 | 1.070 |
Why?
| | Immunoconjugates | 6 | 2024 | 127 | 0.960 |
Why?
| | Androgen Antagonists | 1 | 2024 | 92 | 0.830 |
Why?
| | Sarcoma | 2 | 2018 | 193 | 0.580 |
Why?
| | Dacarbazine | 1 | 2017 | 95 | 0.530 |
Why?
| | Prostatic Neoplasms | 1 | 2024 | 1050 | 0.510 |
Why?
| | Antineoplastic Agents | 2 | 2017 | 2162 | 0.470 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2025 | 255 | 0.430 |
Why?
| | Pyrimidines | 1 | 2017 | 510 | 0.420 |
Why?
| | Sulfonamides | 1 | 2017 | 576 | 0.400 |
Why?
| | Health Services Needs and Demand | 1 | 2015 | 282 | 0.390 |
Why?
| | Neoplasm Metastasis | 5 | 2025 | 674 | 0.360 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2015 | 353 | 0.350 |
Why?
| | Cisplatin | 3 | 2024 | 328 | 0.350 |
Why?
| | Urologic Neoplasms | 4 | 2024 | 30 | 0.330 |
Why?
| | Adenocarcinoma | 1 | 2016 | 897 | 0.290 |
Why?
| | Liver Neoplasms | 1 | 2015 | 741 | 0.290 |
Why?
| | Pancreatic Neoplasms | 1 | 2016 | 890 | 0.270 |
Why?
| | Infusions, Intravenous | 2 | 2016 | 418 | 0.230 |
Why?
| | Aged | 14 | 2026 | 24836 | 0.220 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2017 | 547 | 0.210 |
Why?
| | Carcinoma, Renal Cell | 1 | 2026 | 221 | 0.200 |
Why?
| | Cell Adhesion Molecules | 1 | 2024 | 179 | 0.200 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2025 | 191 | 0.190 |
Why?
| | Aged, 80 and over | 8 | 2025 | 7948 | 0.190 |
Why?
| | Ribonucleoprotein, U2 Small Nuclear | 2 | 2012 | 5 | 0.190 |
Why?
| | Middle Aged | 13 | 2026 | 34658 | 0.180 |
Why?
| | Antigens, Neoplasm | 1 | 2024 | 320 | 0.180 |
Why?
| | Antibodies, Monoclonal | 2 | 2024 | 1456 | 0.180 |
Why?
| | Kidney Neoplasms | 1 | 2026 | 400 | 0.180 |
Why?
| | Male | 17 | 2026 | 70140 | 0.170 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2024 | 189 | 0.170 |
Why?
| | Disease Management | 1 | 2024 | 634 | 0.160 |
Why?
| | Deoxycytidine | 2 | 2019 | 202 | 0.160 |
Why?
| | Phosphoproteins | 2 | 2012 | 332 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 1 | 2026 | 918 | 0.160 |
Why?
| | Liposarcoma | 1 | 2019 | 30 | 0.150 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1243 | 0.150 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 65 | 0.150 |
Why?
| | Gene Amplification | 1 | 2019 | 105 | 0.150 |
Why?
| | Humans | 21 | 2026 | 141284 | 0.140 |
Why?
| | Molecular Targeted Therapy | 2 | 2026 | 420 | 0.140 |
Why?
| | Adult | 11 | 2025 | 39319 | 0.140 |
Why?
| | Female | 16 | 2026 | 75814 | 0.140 |
Why?
| | Disease-Free Survival | 2 | 2017 | 713 | 0.140 |
Why?
| | Biliary Tract Neoplasms | 1 | 2017 | 30 | 0.130 |
Why?
| | Soft Tissue Neoplasms | 1 | 2018 | 120 | 0.130 |
Why?
| | Indazoles | 1 | 2017 | 77 | 0.130 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2016 | 51 | 0.130 |
Why?
| | Treatment Failure | 1 | 2017 | 355 | 0.120 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 43 | 0.120 |
Why?
| | Surgical Procedures, Operative | 1 | 2019 | 270 | 0.120 |
Why?
| | Leucovorin | 1 | 2016 | 86 | 0.120 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2019 | 1075 | 0.120 |
Why?
| | Retrospective Studies | 5 | 2026 | 16447 | 0.120 |
Why?
| | Costs and Cost Analysis | 1 | 2016 | 219 | 0.110 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 94 | 0.110 |
Why?
| | Fluorouracil | 1 | 2016 | 207 | 0.110 |
Why?
| | Immunoglobulin E | 1 | 2016 | 319 | 0.110 |
Why?
| | Disease Progression | 2 | 2024 | 2808 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 543 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2026 | 11216 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 840 | 0.100 |
Why?
| | Myelodysplastic Syndromes | 2 | 2012 | 143 | 0.100 |
Why?
| | Platinum | 2 | 2024 | 51 | 0.100 |
Why?
| | Neovascularization, Pathologic | 1 | 2015 | 295 | 0.100 |
Why?
| | Young Adult | 4 | 2018 | 13727 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 438 | 0.100 |
Why?
| | Anemia, Sideroblastic | 1 | 2012 | 4 | 0.100 |
Why?
| | Haploinsufficiency | 1 | 2012 | 55 | 0.090 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2015 | 428 | 0.090 |
Why?
| | Biomarkers, Tumor | 2 | 2024 | 1250 | 0.090 |
Why?
| | Polycythemia | 1 | 2011 | 24 | 0.090 |
Why?
| | Mutation | 2 | 2012 | 4006 | 0.080 |
Why?
| | Ribonucleoproteins | 1 | 2012 | 103 | 0.080 |
Why?
| | Spondylitis, Ankylosing | 1 | 2011 | 47 | 0.080 |
Why?
| | RNA Splicing | 1 | 2012 | 271 | 0.080 |
Why?
| | Neoplasm Staging | 2 | 2024 | 1397 | 0.080 |
Why?
| | Incidence | 1 | 2016 | 2809 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 334 | 0.080 |
Why?
| | Cytokines | 1 | 2016 | 2079 | 0.070 |
Why?
| | Antirheumatic Agents | 1 | 2011 | 306 | 0.070 |
Why?
| | Nuclear Proteins | 1 | 2012 | 718 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2026 | 108 | 0.060 |
Why?
| | Clinical Studies as Topic | 1 | 2024 | 12 | 0.050 |
Why?
| | Cohort Studies | 2 | 2024 | 5809 | 0.050 |
Why?
| | RNA Splicing Factors | 2 | 2012 | 57 | 0.050 |
Why?
| | Signal Transduction | 1 | 2015 | 5116 | 0.040 |
Why?
| | Organoplatinum Compounds | 1 | 2021 | 50 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 451 | 0.040 |
Why?
| | Negative-Pressure Wound Therapy | 1 | 2018 | 29 | 0.040 |
Why?
| | Pain | 1 | 2024 | 779 | 0.040 |
Why?
| | Multimodal Imaging | 1 | 2018 | 119 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2018 | 243 | 0.030 |
Why?
| | Prognosis | 2 | 2019 | 4080 | 0.030 |
Why?
| | Surgical Flaps | 1 | 2018 | 144 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2019 | 959 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 917 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1979 | 0.030 |
Why?
| | K562 Cells | 1 | 2012 | 95 | 0.020 |
Why?
| | Splicing Factor U2AF | 1 | 2012 | 17 | 0.020 |
Why?
| | Mutation Rate | 1 | 2012 | 29 | 0.020 |
Why?
| | Leukemia, Myeloid | 1 | 2012 | 47 | 0.020 |
Why?
| | Serine-Arginine Splicing Factors | 1 | 2012 | 23 | 0.020 |
Why?
| | Spliceosomes | 1 | 2012 | 50 | 0.020 |
Why?
| | Quality of Life | 1 | 2024 | 3024 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 343 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2019 | 2502 | 0.020 |
Why?
| | Sequence Alignment | 1 | 2012 | 363 | 0.020 |
Why?
| | Janus Kinase 2 | 1 | 2011 | 32 | 0.020 |
Why?
| | Infliximab | 1 | 2011 | 111 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2487 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 757 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 983 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2012 | 373 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5222 | 0.020 |
Why?
| | Mice | 2 | 2019 | 17969 | 0.020 |
Why?
| | Base Sequence | 1 | 2012 | 2170 | 0.020 |
Why?
| | United States | 1 | 2025 | 15298 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7805 | 0.020 |
Why?
| | Adolescent | 2 | 2018 | 22116 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2012 | 3042 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1761 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2012 | 4149 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2012 | 2815 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3172 | 0.010 |
Why?
| | Animals | 2 | 2019 | 37328 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 5866 | 0.010 |
Why?
| | Child | 1 | 2018 | 22390 | 0.010 |
Why?
|
|
Bupathi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|